MET状态对乳头状肾细胞癌治疗结局的影响:历史数据的汇总分析
该回顾性观察研究纳入三个国际注册库中局部晚期或转移性乳头状肾细胞癌患者,用二代测序回顾性判定MET状态,分析MET驱动与MET非依赖肿瘤接受一线治疗后的无进展生存和总生存。在舒尼替尼治疗患者中,MET驱动组中位无进展生存期9.2个月对MET非依赖组5.7个月,HR=0.67,未达统计学显著,两组总生存无差异。
要点
- 308例乳头状肾细胞癌患者中305例接受一线治疗,最常用舒尼替尼208例(68%)。
- 179例有有效二代测序结果者中38%为MET驱动、49%为MET非依赖、13%不可评估。
- 舒尼替尼治疗者MET驱动组中位无进展生存期9.2个月对MET非依赖组5.7个月,HR=0.67,未达统计学显著。
核心结论
- MET驱动型乳头状肾细胞癌可能对靶向药物有反应,但MET改变似乎不能预测当前非生物标志物驱动治疗的结局。
研究设计与样本
- 回顾性观察研究,纳入三个国际注册库中局部晚期或转移性乳头状肾细胞癌患者308例,其中305例接受一线治疗。
- MET状态通过存档组织二代测序回顾性判定,MET驱动定义为MET和/或肝细胞生长因子扩增、7号染色体获得和/或MET激酶域突变。
主要发现
- 305例接受一线治疗者中最常用舒尼替尼208例(68%),其次依维莫司40例(13%)。
- 179例有有效二代测序结果者中38%为MET驱动、49%为MET非依赖、13%不可评估。
- 舒尼替尼治疗患者中,MET驱动组对MET非依赖组中位无进展生存期9.2个月(95%CI:5.4-13.2)对5.7个月(95%CI:4.3-7.4),HR=0.67(95%CI:0.41-1.08),数值上更长但未达统计学显著。
- 两组总生存无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Papillary renal cell carcinoma (PRCC) represents 15% of RCCs but has no indicated therapies, with limited biomarker-based data to inform targeted treatment. MET alterations may be key; > 80% of PRCC tumours show MET upregulation. The objective of this study was to assess MET status in PRCC and its impact on clinical outcomes. METHODS: This retrospective, observational study included patients with locally advanced/metastatic PRCC from three international registries. MET status was determined retrospectively by next generation sequencing (NGS) of archival tissue. MET-driven was defined as MET and/or hepatocyte growth factor amplification, chromosome 7 gain, and/or MET kinase domain mutations. Objectives included progression-free survival (PFS) and overall survival (OS) by MET status using a Cox proportional hazards model. RESULTS: Of 308 patients, 305 received first-line treatment; most commonly sunitinib (n = 208; 68%), then everolimus (n = 40; 13%). Of 179 patients with valid NGS results, 38% had MET-driven and 49% MET-independent tumours (13% unevaluable). In the MET-driven versus MET-independent subgroups, respectively, of sunitinib-treated patients, median PFS was numerically longer, though not statistically significantly; PFS: 9.2 months (95% confidence interval [CI]: 5.4-13.2) versus 5.7 months (95% CI: 4.3-7.4), hazard ratio (HR) = 0.67; 95% CI: 0.41-1.08. There was no difference between the OS of each subgroup. CONCLUSIONS: MET-driven PRCC may respond to targeted agents. However, the presence of MET alterations did not appear to be predictive for outcomes in response to current therapies, which are not biomarker-driven, compared with MET-independent tumours.
引用
- Albiges L, Heng DYC, Lee JL, et al. Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data. Eur J Cancer. 2022. PMID: 35640484. doi:10.1016/j.ejca.2022.04.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。